World Asset Management Inc decreased its stake in shares of AstraZeneca plc (NYSE:AZN) by 0.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,038 shares of the company’s stock after selling 248 shares during the quarter. World Asset Management Inc’s holdings in AstraZeneca were worth $1,570,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in AZN. Dimensional Fund Advisors LP boosted its holdings in shares of AstraZeneca by 3.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,678,067 shares of the company’s stock valued at $101,713,000 after buying an additional 80,891 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of AstraZeneca by 12.1% in the 4th quarter. Geode Capital Management LLC now owns 59,214 shares of the company’s stock valued at $2,248,000 after buying an additional 6,380 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of AstraZeneca in the 4th quarter valued at approximately $439,000. HRT Financial LLC acquired a new stake in shares of AstraZeneca in the 4th quarter valued at approximately $207,000. Finally, Advisory Services Network LLC boosted its holdings in shares of AstraZeneca by 9.4% in the 4th quarter. Advisory Services Network LLC now owns 6,659 shares of the company’s stock valued at $253,000 after buying an additional 570 shares during the last quarter. Institutional investors and hedge funds own 18.79% of the company’s stock.
Several research firms have recently commented on AZN. Zacks Investment Research raised AstraZeneca from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a report on Tuesday, April 16th. Pareto Securities raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday, April 29th. Finally, ValuEngine raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $45.29.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.43. AstraZeneca had a return on equity of 37.25% and a net margin of 9.38%. The business had revenue of $5.72 billion during the quarter, compared to the consensus estimate of $5.57 billion. During the same quarter last year, the firm posted $0.69 EPS. The company’s quarterly revenue was up 10.9% on a year-over-year basis. Equities research analysts forecast that AstraZeneca plc will post 1.79 EPS for the current year.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.